President Trump has taken a tough stance on pharma companies that hike up prices of their drugs. In an attempt to alleviate the public's concerns, the pharma lobby is now touting a "value-based" model that will provide some reimbursement for drugs that don't work all that well.
Bloomberg News reports that this model, sometimes known as pay for performance, has drawn its fair share of criticism. It remains to be seen whether it will have any effect on lowering drug prices. CF